The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia

Experimental Hematology

Volumn 35, Issue 11, 2007, Pages 1704-1707

  Hsiao, Hui Hua ^a,b   Yang, Ming Yu ^c   Liu, Yi Chang ^a,b   Lee, Ching Ping ^b   Yang, Wen Chi ^a,b   Liu, Ta Chih ^a,b   Chang, Chao Sung ^a,b   Lin, Sheng Fung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c FOOYIN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; HEMOGLOBIN;

ADULT; ARTICLE; BLEEDING; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; GENE SEQUENCE; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LEUKOCYTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOCYTHEMIA; THROMBOSIS; ADOLESCENT; AGED; DISEASE MANAGEMENT; GENETICS; GENOTYPE; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE MANAGEMENT; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HEMOGLOBINS; HUMANS; JANUS KINASE 2; LEUKOCYTOSIS; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 35449003577     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.08.011     Document Type: Article

References (26)

1. Sandberg E.M., Wallace T.A., Godeny M.D., Vonderlindern D., and Sayeski P.P. Jak2 tyrosine kinase: a true JAK of all trades?. Cell Biochem Biophys 41 (2004) 207-232
2. Campbell P.J., and Green A.R. The myeloproliferative disorders. N Engl J Med 335 (2006) 2452-2466
3. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
4. Kralovics T., Passamonti F., Buser A.S., et al. A gain-of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 351 (2005) 1779-1790
5. Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106 (2005) 2162-2168
6. Tefferi A., and Gilliland D.G. JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle 4 (2005) 1053-1056
7. Levine R.L., and Gilliland D.G. JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol 14 (2007) 43-47
8. Finazzi G., and Harrison C. Essential thrmobocythemia. Semin Hematol 42 (2005) 230-238
9. Fialkow P.J., Faguet G.B., Jacobson R.J., Vaidya K., and Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 58 (1981) 916-919
10. Wolanskyj A.P., Lasho T.L., Schwager S.M., McClure R.F., Wadleigh M., and Lee S.J. JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Hematol 131 (2005) 208-213
11. Ohyashiki K., Aota Y., Akahane D., Gotoh A., and Ohyashiki J.H. JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. Leukemia 21 (2007) 1097-1099
12. Speletas M., Katodritou E., Daiou C., et al. Correlations of JAK2-V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders. Leuk Res 31 (2007) 1061-1070
13. Pikman Y., Lee B.H., Mercher T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3 (2006) 1140-1151
14. Pardanani A., Levine R.L., Lasho T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006) 3472-3476
15. Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol 36 (1999) 9-13
16. Tefferi A. Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol 13 (2006) 93-98
17. Lippert E., Boissinot M., Kralovics R., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108 (2006) 1865-1867
18. Cheung B., Radia D., Pantedelis P., Yadegarfar G., and Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia. Br J Haematol 132 (2005) 244-245
19. Finazzi G., Rambaldi A., Guerini V., Carobbo A., and Barlin T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92 (2007) 135-136
20. Antonioli E., Guglielmelli P., Pancrazzi A., et al. Clinical implications of the JAK2 V17F mutation in essential thrombocythemia. Leukemia 19 (2005) 1847-1849
21. Carobbio A., Finazzi G., Guerini V., et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and JAK2 mutation status. Blood 15 (2007) 2310-2313
22. Falanga A., Marchetti M., Vignoli A., Balducci D., and Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 33 (2005) 523-530
23. Harrison C.N., Campbell P.J., Buck G., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353 (2005) 33-45
24. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
25. Abe M., Suzuki K., Inagaki O., Sassa S., and Shikama H. A novel MPL point mutation resulting in thrombopoietin-independent activation. Leukemia 16 (2002) 1500-1506
26. W515L/K mutation. Br J Haematol 137 (2007) 244-247